Visa Inc. – Consensus Indicates Potential 30.2% Upside

DirectorsTalk Interviews

Visa Inc. with ticker code (V) now have 37 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 296 and 220 calculating the average target price we see 261.34. Given that the stocks previous close was at 200.71 this is indicating there is a potential upside of 30.2%. The 50 day moving average now sits at 207.77 and the 200 day moving average is 210.2. The company has a market capitalisation of $422,979m. Find out more information at: https://usa.visa.com

The potential market cap would be $550,751m based on the market concensus.

Visa Inc. operates as a payments technology company worldwide. The company facilitates digital payments among consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It operates VisaNet, a transaction processing network that enables authorization, clearing, and settlement of payment transactions. In addition, the company offers card products, platforms, and value-added services. It provides its services under the Visa, Visa Electron, Interlink, VPAY, and PLUS brands. Visa Inc. has a strategic agreement with Ooredoo to provide an enhanced payment experience for Visa cardholders and Ooredoo customers in Qatar. Visa Inc. was founded in 1958 and is headquartered in San Francisco, California.

Share on:

Latest Company News

Diversified Energy gains recognition for sustainability focus

Diversified Energy shortlisted for US IR award recognising ESG alignment and responsible investor engagement.

Dunelm reports solid H1 FY26 sales growth amid challenging market conditions

Dunelm Group plc announced Interim Results for the 26 weeks to 27 December 2025, reporting total sales growth of 3.6% to £926.3m and increased market share despite a softer second quarter.

Bellway reports higher completions and maintains FY26 guidance

Bellway said first-half housing completions rose to 4,702 homes, with revenue up over 6% to £1.51bn, despite softer reservation rates through the autumn.

Verici Dx: Tutivia Set to Disrupt Transplant Monitoring with Real-Time RNA Insights (Video)

Tutivia is turning heads in transplant care. Verici Dx CEO Sara Barrington explains how their RNA-based rejection test is setting new standards in real-world use—and why clinicians and payers are getting on board.

BT Group confirms CEO changes across Openreach and BT International

From 1 April 2026, Katie Milligan will assume the role of CEO of Openreach, with Clive Selley moving to lead BT International.

AstraZeneca Q4 and FY 2025: Strong sales growth and pipeline momentum

Excerpt In FY 2025, AstraZeneca achieved 9% reported revenue growth and a 45% increase in reported EPS, reflecting strong commercial execution and pipeline progress.

    Search

    Search